Published in J Thorac Oncol on May 01, 2007
Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) | NCT00600587
Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients | NCT02526537
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 4.54
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One (2013) 1.32
The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open (2013) 1.18
miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget (2014) 1.04
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther (2013) 1.03
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One (2013) 0.99
Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett (2012) 0.98
Orbital metastases as the first manifestation of lung adenocarcinoma. Case Rep Ophthalmol (2011) 0.97
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol (2008) 0.93
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med (2013) 0.92
Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. Cancer Epidemiol Biomarkers Prev (2009) 0.91
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis (2013) 0.90
Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature. Saudi J Ophthalmol (2013) 0.88
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis. BMC Cancer (2013) 0.88
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol (2011) 0.86
EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med (2013) 0.86
Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol Lett (2012) 0.84
Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer. Oncol Lett (2011) 0.81
Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. PLoS One (2015) 0.81
Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. Onco Targets Ther (2016) 0.80
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). Ann Transl Med (2015) 0.79
Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples. Transl Oncol (2013) 0.79
The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol (2017) 0.78
Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Mol Clin Oncol (2015) 0.78
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China. PLoS One (2016) 0.78
Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One (2017) 0.77
LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study. Medicine (Baltimore) (2015) 0.77
Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study. Radiat Oncol (2015) 0.77
Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med (2016) 0.76
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thorac Cancer (2016) 0.76
Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung. Thorac Cancer (2015) 0.76
Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients. Lung India (2015) 0.76
The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med (2017) 0.75
Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. Chin J Cancer Res (2012) 0.75
Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). J Thorac Dis (2014) 0.75
Acute respiratory distress due to thymoma in a patient treated with TK inhibitor: a case report and review of the current treatment options. Case Rep Oncol (2011) 0.75
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). J Thorac Dis (2015) 0.75
The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations. Medicine (Baltimore) (2016) 0.75
Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer. Onco Targets Ther (2015) 0.75
Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib. Springerplus (2014) 0.75
EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther (2017) 0.75
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer. Oncol Lett (2016) 0.75
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Sci Rep (2015) 0.75
Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer. PLoS One (2016) 0.75
O(6)-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer. Exp Ther Med (2017) 0.75
The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm. Biomed Rep (2017) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 18.18
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Chemically derived, ultrasmooth graphene nanoribbon semiconductors. Science (2008) 7.65
Role of the murine reprogramming factors in the induction of pluripotency. Cell (2009) 7.46
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature (2011) 6.73
Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA (2008) 6.60
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80
Narrow graphene nanoribbons from carbon nanotubes. Nature (2009) 4.66
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA (2012) 4.57
Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet (2012) 4.51
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A (2006) 3.94
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Structure of the human histamine H1 receptor complex with doxepin. Nature (2011) 3.48
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci (2010) 3.38
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation (2004) 3.35
The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology (2005) 3.33
The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology (2005) 3.33
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc Natl Acad Sci U S A (2006) 3.22
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 3.13
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
N-doping of graphene through electrothermal reactions with ammonia. Science (2009) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer (2010) 3.06
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
Relations among positive parenting, children's effortful control, and externalizing problems: a three-wave longitudinal study. Child Dev (2005) 3.03
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest (2009) 3.03
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
ChIP-Seq of transcription factors predicts absolute and differential gene expression in embryonic stem cells. Proc Natl Acad Sci U S A (2009) 2.96
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol (2013) 2.91
Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A (2003) 2.90
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Structure of the human glucagon class B G-protein-coupled receptor. Nature (2013) 2.86
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 2.84
High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation (2008) 2.83
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res (2005) 2.81
Genomic epidemiology of a dengue virus epidemic in urban Singapore. J Virol (2009) 2.74
Nitrogen fixation island and rhizosphere competence traits in the genome of root-associated Pseudomonas stutzeri A1501. Proc Natl Acad Sci U S A (2008) 2.70
Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis. Crit Care Med (2009) 2.68
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature (2005) 2.58
High-throughput identification of transcription start sites, conserved promoter motifs and predicted regulons. Nat Biotechnol (2007) 2.57
Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res (2005) 2.56
The closed state of a H+ channel helical bundle combining precise orientational and distance restraints from solid state NMR. Biochemistry (2002) 2.56
Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS (2003) 2.55
Understanding mother-adolescent conflict discussions: concurrent and across-time prediction from youths' dispositions and parenting. Monogr Soc Res Child Dev (2008) 2.53
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest (2002) 2.52
Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis (2009) 2.50
Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res (2002) 2.45
Task-dependent visual-codebook compression. IEEE Trans Image Process (2011) 2.44
Flavonoids: promising anticancer agents. Med Res Rev (2003) 2.43